Mayne Pharma USA has entered into an agreement to acquire branded pharmaceutical assets from Forest Laboratories for $12 million, with an upfront payment of $10 million, plus as much as $2 million payable quarterly based on future product sales. The products include pain drugs ESGIC, ESGIC PLUS, LORCET and LORCET PLUS brands and related assets.    Additionally, Mayne had also recently acquired the branded ZEBUTAL trademark and related assets in the U.S. from Shionogi Inc., which had sales of $5 ...